SCHEMBL6578352

SCHEMBL6578352

Fc1cc(F)c2sc(Cc3ccccc3)nc2c1F

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AKR1A1 P14550 3/20 0.54
AKR1B1 P15121 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8654684 0.84 AKR1A1 (0.53) AKR1A1AKR1B1
SCHEMBL4706329 0.83 AKR1A1 (0.55) AKR1A1AKR1B1
SCHEMBL8657565 0.81 AKR1A1 (0.56) AKR1A1AKR1B1
SCHEMBL4177715 0.80 AKR1A1 (0.51) AKR1A1AKR1B1
SCHEMBL6629050 0.80 AKR1A1 (0.44) AKR1A1AKR1B1
Hydrochloric Acid SCHEMBL4173571 0.80 AKR1A1 (0.50) AKR1A1AKR1B1
SCHEMBL8660288 0.79 AKR1A1 (0.62) AKR1A1AKR1B1
SCHEMBL13814328 0.79 AKR1A1 (0.47) AKR1A1AKR1B1
SCHEMBL8657562 0.79 AKR1A1 (0.54) AKR1A1AKR1B1
SCHEMBL8396211 0.78 AKR1B1 (0.47) AKR1A1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135124-B1 ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS INST FOR PHARM DISCOVERY INC (US) 2004-04-28 EP disclosed
US-20030018053-A1 Substituted indolealkanoic acids THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC. 2003-01-23 US disclosed
WO-2001051489-A2 METHODS FOR LOWERING URIC ACID LEVELS THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018053-A1 Substituted indolealkanoic acids GPR119, AANAT, AADAT AKR1A1 475/4885AKR1B1 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.